Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 17 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

18%

3 trials in Phase 3/4

Results Transparency

33%

5 of 15 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2

11(64.7%)

Phase 3

3(17.6%)

Phase 1

2(11.8%)

N/A

1(5.9%)

17Total

Phase 2(11)

Phase 3(3)

Phase 1(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT05811247Phase 3Completed

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

Role: lead

NCT05813275Phase 3Completed

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

Role: lead

NCT06566820Phase 3Enrolling By Invitation

Continuation Protocol for Obstructive Sleep Apnea (OSA)

Role: lead

NCT06400615Phase 2Completed

Study That Tests AD109 in Patients Taking GLP-1 Drugs

Role: lead

NCT06525337Not ApplicableActive Not Recruiting

Adherence to Health Coaching with Wearable Devices: Enhancing Patient Engagement and Outcomes

Role: collaborator

NCT05793684Phase 2Completed

AD816 Crossover Study

Role: lead

NCT04445688Phase 2Completed

Crossover Trial of AD036 in Obstructive Sleep Apnea

Role: lead

NCT04905979Phase 2Completed

Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

Role: lead

NCT05101122Phase 1Completed

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

Role: lead

NCT04580394Phase 2Completed

Crossover Trial of AD109 in Obstructive Sleep Apnea

Role: lead

NCT03845023Phase 2Completed

Trial of AD036 in Obstructive Sleep Apnea

Role: lead

NCT04631107Phase 2Completed

AD109 Dose Finding in Mild to Moderate OSA

Role: lead

NCT05071612Phase 2Completed

Parallel Arm Trial of AD109 and AD504 In Patients With OSA

Role: lead

NCT04645524Phase 2Completed

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

Role: lead

NCT03892772Phase 1Completed

Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea

Role: collaborator

NCT04611750Phase 2Completed

Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing

Role: collaborator

NCT04394143Phase 2Completed

Effect of AD128 to Treat Obstructive Sleep Apnea

Role: collaborator

All 17 trials loaded